Ilumetri® is the official global commercial brand name, and Yiluqu is its Chinese brand name. It is a humanized IgG1κ monoclonal antibody targeting interleukin‑23 (IL‑23). It selectively binds to the p19 subunit of IL‑23, inhibits IL‑23-mediated inflammatory signaling, suppresses abnormal Th17 immune response and alleviates skin inflammatory lesions related to psoriasis.
Main Indications
Treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Clinical Research
Multiple global multicenter Phase III randomized controlled trials confirmed that tildrakizumab achieves significant, sustained improvement in psoriasis skin lesions. A high proportion of patients attained PASI 75, PASI 90 and PASI 100 responses. Long-term extension studies demonstrated durable efficacy and consistent safety profile over years of subcutaneous administration.
Common Side Effects
Severe risks: Serious infections, hypersensitivity reactions.
Common mild adverse reactions: Upper respiratory tract infection, headache, injection site reactions, back pain, diarrhea, nausea.
Approval Status in China
Original drug Ilumetri® (Tildrakizumab Injection, Chinese brand name: Yiluqu®) was officially approved for marketing in China in 2023, with the specification of 100mg (1mL) single-dose prefilled syringe. It is a prescription biologic medicine for dermatological treatment.
Buy Ilumetri (Tildrakizumab Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
